Literature DB >> 12556655

Evaluation of angiotensin II receptor blockers for 24-hour blood pressure control: meta-analysis of a clinical database.

Joel Neutel1, David H G Smith.   

Abstract

Angiotensin II receptor blockers are well tolerated and improve compliance in hypertensive patients. The need for 24-hour blood pressure control has focused attention on whether all agents in this class maintain smooth antihypertensive effects over a 24-hour period. Insight into this issue emerged from a meta-analysis of five large, multicenter trials in which ambulatory blood pressure monitoring was used to compare the antihypertensive effects of three angiotensin II receptor blockers: telmisartan, losartan, and valsartan. These trials used either a double-blind, placebo-controlled or a prospective, randomized, open-label, blinded-end point design. Initial analysis established the validity of combining ambulatory blood pressure monitoring data from the double-blind, placebo-controlled and prospective, randomized, open-label, blinded-end point designs. Subsequent analyses revealed that telmisartan 80 mg was significantly more effective than losartan 50 mg and valsartan 80 mg for reducing 24-hour mean blood pressure. Furthermore, telmisartan 80 mg was comparable to amlodipine 5 mg for controlling the early morning surge in blood pressure. Copyright 2003 Le Jacq Communications, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12556655      PMCID: PMC8101823          DOI: 10.1111/j.1524-6175.2003.01612.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  34 in total

1.  1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee.

Authors: 
Journal:  J Hypertens       Date:  1999-02       Impact factor: 4.844

Review 2.  Drug treatment of hypertension: the reduction of pulse pressure does not necessarily parallel that of systolic and diastolic blood pressure.

Authors:  M E Safar; A Rudnichi; R Asmar
Journal:  J Hypertens       Date:  2000-09       Impact factor: 4.844

3.  A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine.

Authors: 
Journal:  Blood Press Monit       Date:  1998-10       Impact factor: 1.444

4.  Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation.

Authors:  G Mancia; A Zanchetti; E Agabiti-Rosei; G Benemio; R De Cesaris; R Fogari; A Pessina; C Porcellati; A Rappelli; A Salvetti; B Trimarco; E Agebiti-Rosei; A Pessino
Journal:  Circulation       Date:  1997-03-18       Impact factor: 29.690

5.  Circadian variation in the frequency of onset of acute myocardial infarction.

Authors:  J E Muller; P H Stone; Z G Turi; J D Rutherford; C A Czeisler; C Parker; W K Poole; E Passamani; R Roberts; T Robertson
Journal:  N Engl J Med       Date:  1985-11-21       Impact factor: 91.245

6.  Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy.

Authors:  J R Benz; H R Black; A Graff; A Reed; S Fitzsimmons; Y Shi
Journal:  J Hum Hypertens       Date:  1998-12       Impact factor: 3.012

7.  Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components.

Authors:  J H MacKay; K E Arcuri; A I Goldberg; S M Snapinn; C S Sweet
Journal:  Arch Intern Med       Date:  1996-02-12

8.  Efficacy and tolerability of valsartan in combination with hydrochlorothiazide in essential hypertension.

Authors:  W D Hall; R Montoro; T Littlejohn; A Jain; N Feliciano; H Zheng
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

9.  Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias.

Authors:  S MacMahon; R Peto; J Cutler; R Collins; P Sorlie; J Neaton; R Abbott; J Godwin; A Dyer; J Stamler
Journal:  Lancet       Date:  1990-03-31       Impact factor: 79.321

Review 10.  A chronotherapeutic approach to effective blood pressure management.

Authors:  Peter A Meredith
Journal:  J Clin Hypertens (Greenwich)       Date:  2002 Jul-Aug       Impact factor: 3.738

View more
  10 in total

Review 1.  Guiding antihypertensive treatment decisions using ambulatory blood pressure monitoring.

Authors:  Giuseppe Mancia; Gianfranco Parati
Journal:  Curr Hypertens Rep       Date:  2006-08       Impact factor: 5.369

2.  Industry pulse : editorial development by adis international limited, Italy.

Authors: 
Journal:  High Blood Press Cardiovasc Prev       Date:  2005-09

3.  Safety of telmisartan in patients with arterial hypertension : an open-label observational study.

Authors:  Martin C Michel; Herbert Bohner; Jürgen Köster; Rafael Schäfers; Uwe Heemann
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

4.  Telmisartan and amlodipine single-pill combinations vs amlodipine monotherapy for superior blood pressure lowering and improved tolerability in patients with uncontrolled hypertension: results of the TEAMSTA-5 study.

Authors:  Steen Neldam; Margreet Lang; Russell Jones
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-04-22       Impact factor: 3.738

5.  An effectiveness study comparing algorithm-based antihypertensive therapy with previous treatments using conventional and ambulatory blood pressure measurements.

Authors:  Michael A Weber; William B White; Thomas D Giles; George L Bakris; Joel M Neutel; David Hg Smith; Giora Davidai
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-04       Impact factor: 3.738

6.  Results of increasing doses of hydrochlorothiazide in combination with an angiotensin receptor blocker in patients with uncontrolled hypertension.

Authors:  Steen Neldam; Colin Edwards
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-08       Impact factor: 3.738

7.  Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome.

Authors:  Cristiana Vitale; Giuseppe Mercuro; Carlotta Castiglioni; Alessandra Cornoldi; Arianna Tulli; Massimo Fini; Maurizio Volterrani; Giuseppe M C Rosano
Journal:  Cardiovasc Diabetol       Date:  2005-05-15       Impact factor: 9.951

8.  Effect of hydrochlorothiazide in addition to telmisartan/amlodipine combination for treating hypertensive patients uncontrolled with telmisartan/amlodipine: a randomized, double-blind study.

Authors:  Jitsuo Higaki; Issei Komuro; Kosuke Shiki; Ganghyuck Lee; Atsushi Taniguchi; Hiroshi Ikeda; Daisuke Kuroki; Seiichiro Nishimura; Toshio Ogihara
Journal:  Hypertens Res       Date:  2016-10-20       Impact factor: 3.872

9.  Effect of parathyroid hormone-related protein on intracellular calcium ion and cyclic adenosine monophosphate concentrations in cardiac fibroblasts.

Authors:  Ping Zhou; Qiong Xiao; Zhao-Ting Su; Lin Zhu; Fang-Xia Jin; Xuan-Yi Du
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671

10.  Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study.

Authors:  Jeong Bae Park; Ki-Chul Sung; Seok-Min Kang; Eun Joo Cho
Journal:  Am J Cardiovasc Drugs       Date:  2013-02       Impact factor: 3.571

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.